Norvaline

Other Names

(2R)-2-Aminopentanoic acid(2R)-2-Aminovaleric acid(2S)-2-Aminopentanoic acid(2S)-2-Aminovaleric acid(R)-2-Aminopentanoic acid(R)-2-Aminovaleric acid(R)-norvaline(S)-2-Aminopentanoic acid(S)-2-Aminovaleric acid(S)-norvaline2-Amino-pentanoic acid2-Aminopentanoic acid2-Aminovaleric acidalpha-Aminovaleric acidalpha-DL-Aminopentanoic acidalpha-L-Aminopentanoic acidD-2-Aminopentanoic acidD-2-Aminovaleric acidD-NorvalineD-NvaDL-2-Aminopentanoic acidDL-2-Aminovaleric acidDL-alpha-Aminovaleric acidDL-NorvalineH-D-Nva-OHH-L-Nva-OHH-Nva-OHL-2-Aminopentanoic acidL-2-Aminovaleric acidL-NorvalineL-Nvalaevo-norvalineNorvalinNorvaline, D-NORVALINE, DL-Norvaline, L-NvaPentanoic acid, 2-amino-Pentanoic acid, 2-amino-, (S)-Valeric acid, 2-amino-

Synopsis

Norvaline (L-Norvaline): A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

Chemical Identity

Norvaline (abbreviated as Nva) is an amino acid with the molecular formula CH₃(CH₂)₂CH(NH₂)CO₂H. The compound is a structural analog of valeric acid and also an isomer of the more common amino acid valine. Like most other α-amino acids, norvaline is chiral. It is a white, water-soluble solid. Norvaline is a non-proteinogenic unbranched-chain amino acid, meaning it is not encoded by the standard genetic code and is not directly incorporated into proteins through normal ribosomal translation. It is isomeric with the proteinogenic amino acid valine and can compete with valine for misrecognition by isoleucyl-tRNA synthetase (IleRS).

The compound exists as two enantiomers. The biologically active and commercially relevant form used in dietary supplements is the L-enantiomer (L-norvaline), which is the stereoisomer discussed throughout this article unless otherwise noted. The CAS registry number for L-norvaline is 6600-40-4.

Natural Occurrence

Norvaline has been reported to be a natural component of an antifungal peptide of Bacillus subtilis. Norvaline and norleucine are absent from the standard inventory of protein amino acids; their well-documented intracellular accumulation results from the low substrate specificity of branched-chain amino acid biosynthetic enzymes that act over a number of related α-ketoacids.

Earlier experiments have convincingly shown that norvaline and norleucine are formed from pyruvate being an alternative substrate of α-isopropylmalate synthase. Oxygen limitation causes norvaline accumulation in E. coli K-12 W3110 during growth in glucose-based mineral salt medium. Norvaline is an unusual non-proteinogenic branched-chain amino acid which has been of particular interest in enzymological studies on regulatory mutants of the branched-chain amino acid pathway in Serratia marcescens. More recently, norvaline and other modified amino acids of the branched-chain amino acid synthesis pathway attracted attention when they were found to be incorporated in minor amounts in heterologous proteins with a high leucine or methionine content.

L-Norvaline is generally identified naturally in foods such as dairy, meats, grains, legumes like soy, and nuts like peanuts. However, therapeutic doses typically exceed what is practical to obtain from food alone. For industrial and supplement purposes, L-norvaline is manufactured by synthesis or fermented by bacteria such as E. coli.

Relationship to Protein Biosynthesis

The lack of absolute substrate specificity of leucyl-tRNA synthase leads to a mischarged norvalyl-tRNA^Leu that evades translational proofreading activities and produces norvaline-containing proteins (Apostol et al., J Biol Chem 272:28980–28988, 1997). The molecular event of norleucine and norvaline incorporation into a nascent peptide chain occurs via misaminoacylation of the cognate tRNA. Following the isostructural properties of norvaline for leucine and norleucine for methionine, tRNA^Leu and tRNA^Met are mischarged by aminoacyl-tRNA synthetases, producing corresponding substitutions in the protein sequence. This misincorporation phenomenon is well studied in the context of recombinant biopharmaceutical manufacturing and has implications for understanding norvaline's potential biological effects at high concentrations.

Research examining the effect of amino acid substitution in model peptides showed that norvaline has a notably destructive effect on β-sheet secondary structure, and that the higher toxicity of norvaline over valine is predominantly due to misincorporation within β-sheet secondary elements.

2. Common Forms and Preparations

Norvaline is available commercially in several formats for use as a dietary supplement:

Free-form powder: L-norvaline is sold as a bulk powder (unflavored) for mixing into beverages or pre-workout drinks. Manufacturers produce it in quantities ranging from a few grams to kilogram lots.
Capsules: Encapsulated norvaline products allow for more convenient and precise dosing.
Multi-ingredient pre-workout blends: L-Norvaline is typically sold in its standard 'L-Norvaline' form; no commonly recognized alternative or trademarked forms have been documented. It appears predominantly as a component of "pump"-focused pre-workout formulas rather than as a standalone product.

Norvaline is used in the dietary supplement industry to inhibit the enzyme arginase and thus reduce the conversion of arginine to urea. Norvaline, by itself, has no vasodilating properties, although it enhances the vasodilating properties of arginine.

3. Traditional and Historical Use

Unlike many botanical dietary supplements, norvaline does not have a documented history of use in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbalism. It is not a herb, plant extract, or herbal preparation.

Norvaline's entry into the broader scientific and supplement literature emerged from mid-to-late 20th-century biochemistry. Its primary context was first as a laboratory tool — a pharmacological inhibitor used in cell and animal experiments to probe the functions of arginase. The 1998 publication by Bhatt et al. in Biochemistry and Biophysics Research Communications and the seminal 1997 work by Apostol et al. in the Journal of Biological Chemistry identifying norvaline's misincorporation into recombinant hemoglobin in E. coli brought broader scientific attention to this molecule. Only subsequently did it migrate into sports nutrition formulations, primarily in the 2000s–2010s, as understanding of its arginase-inhibitory properties became popularized.

It is well known that some non-proteinogenic amino acids (NPAAs) are toxic through their ability to mimic protein amino acids, either in protein synthesis or in other metabolic pathways, and this property is utilized by some plants to inhibit the growth of other plants or kill herbivores. Norvaline's occurrence in microbial antifungal peptides (as noted in Bacillus subtilis) suggests that its biological activity has evolved as a defense mechanism rather than as a metabolically central molecule.

In summary, norvaline has no established ethnobotanical or traditional medicinal history. Its use as a supplement is entirely a modern phenomenon rooted in pharmacological research, not in historical or cultural tradition.

4. Key Constituents and Mechanisms of Action

Because norvaline is a single, defined chemical entity rather than a botanical extract, the discussion of "key constituents" is focused on the molecule itself and its known biochemical mechanisms.

4.1 Arginase Inhibition and the Nitric Oxide Pathway

The primary and most thoroughly documented mechanism of L-norvaline is non-competitive inhibition of the enzyme arginase.

In macrophages and many other cell types, L-arginine is used as a substrate by both nitric oxide synthase (NOS) and arginase to produce nitric oxide (NO) and urea, respectively. Because the availability of L-arginine is a major determinant for NO synthesis in the activated macrophage, arginase can reduce NO production by depleting the common substrate.

Arginase inhibits the production of nitric oxide via several potential mechanisms, including competition with NOS for the substrate L-arginine, uncoupling of NOS resulting in the generation of the NO scavenger superoxide and peroxynitrite, repression of the translation and stability of inducible NOS protein, inhibition of inducible NOS activity via the generation of urea, and sensitization of NOS to its endogenous inhibitor, asymmetric dimethyl-L-arginine.

L-norvaline (Norv), as a natural arginase inhibitor, increases the endogenous stock of L-arginine, improving NO production, therefore promoting a healthier endothelium. Norvaline is an efficient non-competitive arginase inhibitor, and this feature is likely responsible for its neuroprotective properties.

A landmark cell-based experiment demonstrated the magnitude of this effect: L-norvaline at 10 mM, which specifically inhibits arginase activity (reducing urea production by 50%) without altering NOS activity, enhanced NO production by 55% from activated macrophages. The enhancement of NO production by L-norvaline was inversely related to the extracellular level of L-arginine. A more pronounced increase in NO production was observed at the lower level of extracellular L-arginine (a 55% vs. 28% increase for 0.05 and 0.1 mM extracellular L-arginine, respectively). When the L-arginine concentration exceeded 0.5 mM, the L-norvaline effect was abolished. This observation has important implications for supplement use: the arginase-inhibitory action may be most relevant when arginine availability is limited.

4.2 S6K1 (Ribosomal Protein S6 Kinase β-1) Inhibition and Anti-inflammatory Effects

A second, independent mechanism was identified by Ming et al. (2009): the arginase inhibitor L-norvaline exhibits anti-inflammatory effects independently of inhibition of arginase in human endothelial cells; the anti-inflammatory properties of L-norvaline are partially attributable to its ability to inhibit S6K1.

The inhibitory effect of L-norvaline was not reversed by the NOS inhibitor L-NAME, and L-norvaline did not interfere with TNFα-induced activation of NF-κB, JNK, or p38mapk, while it inhibited p70s6k (S6K1) activity. Silencing S6K1 prevented up-regulation of E-selectin, but not that of VCAM-1 or ICAM-1 induced by TNFα. The arginase inhibitor L-norvaline exhibits anti-inflammatory effects independently of inhibition of arginase in human endothelial cells. The anti-inflammatory properties of L-norvaline are partially attributable to its ability to inhibit S6K1.

The induction of the expression of endothelial VCAM-1, ICAM-1 and E-selectin by TNFα was concentration-dependently reduced by incubation of the endothelial cells with the arginase inhibitor L-norvaline. However, inhibition of arginase by another arginase inhibitor S-(2-boronoethyl)-L-cysteine (BEC) had no effects, confirming that the anti-inflammatory action operates through a separate mechanism beyond arginase inhibition per se. This effect of L-norvaline must be taken into account when the drug is used to study functions of arginase or NO production in biological systems. The results of this study also implicate that L-norvaline or its derivatives may be useful drugs to treat inflammatory responses in the cardiovascular system and to prevent cardiovascular diseases.

4.3 mTOR Pathway Modulation

S6K1 is a direct downstream effector of the mechanistic target of rapamycin (mTOR) complex. An interaction between the arginase II (ARGII) and mTOR-ribosomal protein S6 kinase β-1 (S6K1) pathways promotes inflammation and oxidative stress. In murine studies, L-norvaline, which inhibits both arginase and S6K1, was used to investigate these combined effects. Bioinformatics analysis revealed that L-norvaline treatment activates neuregulin signaling, synaptic long-term depression, ERK/MAPK signaling, PDGF signaling, and oncostatin M signaling pathways, which are essential for neuroprotection. The full scope of mTOR pathway engagement by norvaline in living humans is not established.

4.4 Urea Cycle Modulation

Arginase redirects the metabolism of L-arginine to L-ornithine and the formation of polyamines and L-proline, which are essential for smooth muscle cell growth and collagen synthesis. Induction of arginase may therefore promote aberrant vessel wall remodeling and neointima formation. By inhibiting arginase, L-norvaline attenuates this metabolic diversion. Norvaline is capable of correcting AD-related arginine metabolism aberrations by inhibiting two central enzymes of the urea cycle.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular and Endothelial Function

Preclinical (animal) evidence: Multiple studies in rodent models of hypertension have investigated L-norvaline's effects on vascular function.

Upregulation of arginase inhibits endothelial NOS-mediated NO synthesis and may contribute to endothelial dysfunction in hypertension, aging, ischemia-reperfusion, and diabetes.

Norvaline given for 7 days at a dose of 10 mg/kg/day has been shown to prevent the development of systemic endothelial dysfunction in L-NAME and methionine-induced NO deficiency in rats (Pokrovskiy et al., 2011). Several studies in rats with stress-induced arterial hypertension have shown L-norvaline to protect the endothelium, reduce blood pressure, and induce diuresis (Gilinsky et al., 2020; Konovalova and Chernomortseva, 2019; Pokrovskiy et al., 2011; Polis et al., 2019).

In one study, experimental animals were intraperitoneally administered for seven days with L-norvaline (30 mg/kg/day), a potent arginase inhibitor, or with vehicle. El-Bassossy et al. (2013) demonstrated that arginase inhibition alleviates fructose-induced hypertension in a rat model of metabolic syndrome. The authors gavaged experimental animals with solutions of L-citrulline, L-norvaline (50 mg/kg/day), and L-ornithine for six weeks.

Research examined correction of endothelial dysfunction with the arginase inhibitor L-norvaline. There is an imbalance between vasoconstriction and vasodilatation factors of endothelium on the basis of endothelial dysfunction. Nitrogen oxide plays the basic role among vasodilatation agents. Amino acid L-arginine serves as a source of molecules of nitrogen oxide. Because of the high activity of arginase, which catalyzes the hydrolysis of L-arginine into ornithine and urea, the bioavailability of nitrogen oxide decreases. Inhibitors of arginase suppress the activity of this enzyme, raising production of nitrogen oxide and preventing the development of endothelial dysfunction.

Upregulation of arginase has been demonstrated in both diabetic patients and animal models of hyperglycemia and type 2 diabetes. L-norvaline is a nonselective inhibitor of arginase that increases NO production and promotes the normal functioning of the vascular endothelium.

Limitations: All cardiovascular studies with L-norvaline in intact animals have been conducted in rodent models using intraperitoneal injection or gavage. No controlled human clinical trials evaluating L-norvaline's effects on blood pressure, endothelial function, or cardiovascular biomarkers have been identified in the published literature as of this writing. The evidence base is therefore preclinical only and cannot be extrapolated directly to human supplement use.

5.2 Exercise Performance and Athletic Use

Proposed mechanism in sport: Norvaline is used in the dietary supplement industry to inhibit the enzyme arginase and thus reduce the conversion of arginine to urea. Norvaline, by itself, has no vasodilating properties, although it enhances the vasodilating properties of arginine.

Evidence quality: Although the theory may encourage use of norvaline, there are hardly any human studies that demonstrate its effectiveness, especially in sport. Preclinical and mechanistic research suggests potential benefits for exercise tolerance, nitric oxide-related pathways, and recovery; however, human clinical studies confirming these effects are currently limited.

Some preclinical studies, including in vitro and animal models, have demonstrated norvaline's ability to inhibit arginase activity and increase NO levels, suggesting a possible benefit in cardiovascular and cognitive health. In sports nutrition, these effects are hypothesized to contribute to improved blood flow, endurance, and muscle recovery. However, clinical evidence in humans is limited. A few small studies have reported promising results, such as increased NO metabolites and improved exercise performance, but these findings require confirmation in larger, well-controlled trials.

Overall assessment: There are no published, peer-reviewed, randomized controlled trials in human athletes or healthy exercising populations demonstrating that L-norvaline supplementation meaningfully improves exercise performance, increases muscle mass, enhances recovery, or elevates circulating nitric oxide metabolites beyond what is achieved with arginine or citrulline alone. While norvaline is a promising ingredient with a plausible mechanism of action, more rigorous research is needed to fully validate its efficacy and safety in humans.

5.3 Neurology: Alzheimer's Disease and Cognitive Function

Research into L-norvaline's potential neuroprotective role has been among the most scientifically substantive areas of investigation, though it remains at the preclinical stage.

The urea cycle is strongly implicated in the pathogenesis of Alzheimer's disease (AD). Arginase-I (ARGI) accumulation at sites of amyloid-beta (Aβ) deposition is associated with L-arginine deprivation and neurodegeneration. An interaction between arginase II (ARGII) and mTOR-ribosomal protein S6 kinase β-1 (S6K1) pathways promotes inflammation and oxidative stress.

A substantial decay of neurogenesis has been documented in Alzheimer's disease patients and animal AD models; however, several treatment strategies can halt further decline and even induce neurogenesis. Previous results indicated a potential effect of arginase inhibition, with norvaline, on various aspects of neurogenesis in triple-transgenic mice. To better evaluate this effect, researchers chronically administered norvaline to triple-transgenic and wild-type mice and applied an advanced immunohistochemistry approach with several biomarkers.

Key findings from the Polis et al. (2018) study in Neurotherapeutics using the triple-transgenic (3×Tg) mouse model of Alzheimer's disease: Mice were treated with L-norvaline, which inhibits both arginase and S6K1. The acquisition of spatial memory was significantly improved in the treated 3×Tg mice, and the improvement was associated with a substantial reduction in microgliosis. In these mice, increases in the density of dendritic spines and expression levels of neuroplasticity-related proteins were followed by a decline in the levels of Aβ toxic oligomeric and fibrillar species in the hippocampus.

Using high-resolution light microscopy and analysis of the density of dendritic spines in cortical and hippocampal neurons, a notable increase in the number of dendritic spines was also detected in 3×Tg-AD mice treated with the arginase inhibitor. These findings suggest potent ameliorative effects of norvaline on synaptic homeostasis and integrity of synaptic connections in 3×Tg-AD mice. The reduction in plaque load and neuroprotective effects of L-norvaline correlated with modulation of microglial activity in the 3×Tg-AD mouse brain, as evident from reduced Iba1 immunoreactivity, as well as increased viability of astrocytes in the hippocampal and cortical slices.

In the original studies in a rodent model of AD, mice were treated with the arginase inhibitor non-proteinogenic BCAA norvaline. The animals treated with norvaline demonstrated significantly improved spatial memory acquisition, associated with an increase in hippocampal spine density and reduced neuroinflammation. Moreover, the rate of brain amyloidosis was significantly diminished due to a reduction in the expression levels of APP, which was followed by a significant increase in [Cu-Zn] superoxide dismutase levels, suggesting improvement of the internal antioxidant mechanisms.

L-norvaline is a potent non-competitive arginase inhibitor. Contemporary studies have identified arginase function in the brain and associated this enzyme with the development of neurodegenerative diseases. Moreover, upregulation of arginase contributes to endothelial dysfunction, atherosclerosis, and diabetes. Regulation of arginase activity is therefore an emerging universal approach for treatment of AD and other metabolic disorders.

Arginase inhibition, in general, shows wide-ranging therapeutic potential for the treatment of various pathologies. The multifaceted modes of L-norvaline activity interfere with several critical aspects of AD pathogenesis. Therefore, the substance represents a promising neuroprotective agent that deserves to be clinically investigated.

Since previous observations indicated that the urea cycle may have a role in the Alzheimer's disease process, researchers quantified the expression of each gene involved in the urea cycle in control and AD brains. They confirmed that all the urea cycle enzyme genes are expressed in the AD brain. The expression of arginase 2 was greater in the AD brain than in the control brain. The presence of the rare arginase 2 allele rs742869 was associated with an increase in the risk of AD in men and with an earlier age at onset for both genders.

Limitations: All neurological research with L-norvaline has been conducted in transgenic mouse models of Alzheimer's disease or in cell culture. No human clinical trials of L-norvaline for cognitive function, Alzheimer's disease, or any other neurological condition have been published. Early research has explored L-norvaline's possible neuroprotective properties, particularly in the context of neurodegenerative diseases. However, much of this evidence is preliminary and based on animal models. Large, well-controlled clinical trials in humans are still limited.

5.4 Metabolic Syndrome, Diabetes, and Hyperglycemia

Hyperglycemia and hypercholesterolemia are associated with increased oxidative stress that leads to reduced nitric oxide bioavailability through disruption of L-arginine transport into cells, inactivation of nitric oxide synthase, and activation of arginase. Upregulation of arginase has been demonstrated in both diabetic patients and animal models of hyperglycemia and type 2 diabetes.

Whether L-norvaline and L-arginine have antihyperglycemic effects had not been previously studied in depth. Researchers hypothesized that inhibition of arginase will provide an antihyperglycemic effect and, as a result of the recovery of NO bioavailability, will protect against oxidative stress and hypercholesterolemia. Rats were fed a high-fat diet for three weeks concomitant with two-time injection of 30 mg/kg streptozotocin to induce stable hyperglycemia. They studied the antihyperglycemic properties of arginase inhibition via L-norvaline and its combination with NOS substrate supplementation via L-arginine.

Limitations: Research in this domain is animal-based (rat models of induced hyperglycemia and metabolic syndrome). No human trials of L-norvaline for blood glucose control, insulin sensitivity, or metabolic syndrome management have been identified.

5.5 Inflammation and Vascular Adhesion

The 2009 study by Ming et al. in BMC Cardiovascular Disorders — conducted in human umbilical vein endothelial cells (HUVECs) — provides one of the most mechanistically detailed sets of in vitro data on L-norvaline. Human endothelial cells were isolated from umbilical veins and stimulated with TNFα (10 ng/ml) for 4 hours. Endothelial expression of inflammatory molecules — VCAM-1, ICAM-1, and E-selectin — were assessed by immunoblotting. The induction of the expression of endothelial VCAM-1, ICAM-1 and E-selectin by TNFα was concentration-dependently reduced by incubation of the endothelial cells with the arginase inhibitor L-norvaline. This was an in vitro study; it does not demonstrate anti-inflammatory benefit in living humans.

6. Body Systems and Health Areas of Association

Cardiovascular system: L-norvaline's arginase-inhibitory properties link it to endothelial NO production, vascular tone regulation, blood pressure modulation, and atherosclerosis-related pathways. Research provides accumulating evidence for the involvement of arginase in decreased endothelial NO production through competition with eNOS for the substrate L-arginine. An increasing number of studies show that enhanced arginase gene expression or activity contributes to endothelial dysfunction in various cardiovascular disorders including atherosclerosis.
Immune and inflammatory pathways: Via S6K1 inhibition and direct suppression of endothelial adhesion molecule expression, L-norvaline interacts with inflammatory signaling, as studied in vitro in human endothelial cells.
Nervous system and neurodegeneration: The urea cycle and arginine metabolism axis in the AD brain connects L-norvaline's mechanism to neuroinflammation, amyloid deposition, and synapse maintenance, all studied in mouse models.
Metabolic pathways: Through effects on arginase and the arginine/ornithine/urea cycle, norvaline may influence glucose metabolism, cholesterol levels, and oxidative stress in metabolic syndrome contexts, as evidenced in animal studies.
Muscle and exercise physiology: L-norvaline is hypothesized to support exercise-related muscle perfusion by potentiating arginine-driven NO production; no direct clinical data exist.
Protein biosynthesis quality control: Norvaline and other modified unbranched-chain amino acids have received attention because they appear to be incorporated in some recombinant proteins found in E. coli, making it relevant to biopharmaceutical manufacturing quality control.

7. Dosage: Forms Reported in Studies and Commercial Products

Animal study dosages (not directly applicable to humans):

Norvaline given for 7 days at 10 mg/kg/day has been shown to prevent the development of systemic endothelial dysfunction in rat models.
One study used intraperitoneal administration for seven days at 30 mg/kg/day.
In the El-Bassossy et al. study, rats were gavaged with L-norvaline at 50 mg/kg/day for six weeks.
In the macrophage in vitro experiment, L-norvaline at 10 mM inhibited arginase activity by 50% and enhanced NO production by 55%.

Commercial supplement dosages:

A survey of 14 commercial products containing L-norvaline found doses ranging from 50 mg to 250 mg per serving, with a median dose of 100 mg.
Without clinical data, it is impossible to define a minimum effective dose or clinical standard dose.
Most research uses 500 mg daily according to one evidence database, though this figure appears to reference animal study dose conversions rather than established human clinical dosing from prospective trials.

In summary, no human dose–response studies for norvaline supplementation have been published. Commercial products typically include between 50 mg and 500 mg per serving. The absence of pharmacokinetic data (oral bioavailability, Tmax, half-life in humans) represents a substantial gap in the available evidence.

8. Safety Considerations

8.1 In Vitro Cytotoxicity Controversy

A study by Samardzic and Rodgers (2019), published in Toxicology in Vitro, raised concerns about L-norvaline's safety. L-norvaline is an NPAA readily available for purchase as a dietary supplement. In light of previous evidence of L-norvaline's antifungal, antimicrobial, and herbicidal activity, the authors examined the toxicity of L-norvaline to mammalian cells in vitro and showed that L-norvaline decreased cell viability at concentrations as low as 125 μM, caused necrotic cell death and significant changes to mitochondrial morphology and function. Furthermore, toxicity was reduced in the presence of structurally similar protein amino acids, suggesting L-norvaline's cytotoxicity could be attributed to protein amino acid mimicry.

This finding was critically evaluated in a response published in Brain Sciences (2019) by Polis et al. The title of the Samardzic/Rodgers study may be greatly overstated; these authors provided several arguments showing that norvaline is not as toxic as reported. Their critique made several substantive points:

The concentrations used in the study may reduce cell viability at above 125 µM, but not for norvaline itself. In fact, it is well-established that most amino acids at concentrations approximately 100 µM and above are cytotoxic in vitro.
The authors utilized L-norvaline at concentrations of 500 and 2000 µM, with and without L-NAME, a nitric oxide synthase inhibitor. Mitochondrial dysfunction is shown to be significant only in the presence of 200 µM L-NAME and at L-norvaline concentrations of 2000 µM. Thus, the assertion that L-norvaline alone leads to mitochondrial dysfunction is unfounded.
L-norvaline is able to be a substrate for branched-chain amino acid aminotransferase (BCAT), which is present in neurons and glial cells. BCAT catalyzes the conversion of branched-chain amino acids and α-ketoglutarate into branched-chain α-keto acids and glutamate. Therefore, the cytotoxic effect of L-norvaline in SH-SY5Y cells might be glutamate- and calcium-mediated.

The method in which L-norvaline caused neuronal cell death may be due to its starving the brain cells of energy, as tests showed it did not reduce the amount of mitochondria but decreased their size. Researchers found that by increasing the concentration of the three BCAAs (leucine, isoleucine, and valine), it was possible to fully protect against the toxic effects of L-norvaline. The BCAAs are also the amino acids most closely related in structure to L-norvaline. As a result, the BCAAs may limit L-norvaline's uptake into the cell by blocking system L transporters, the group responsible for transporting large, neutral amino acids into the cell.

8.2 Competitive Transport with Essential Amino Acids

Four hours after feeding a meal containing norvaline, concentrations of branched-chain amino acids were low in plasma, brain, liver, and muscle. Decreases, especially in brain amino acid concentrations, may result from selective competition by analogues of a given transport class with natural amino acids transported from blood into the brain. This competitive transport dynamic means that high-dose norvaline supplementation could theoretically reduce the availability of essential branched-chain amino acids in certain tissues, though the doses at which this occurs in humans, and its clinical relevance, remain undefined.

8.3 Misincorporation Risk

Norvaline is isomeric with proteinogenic amino acid valine and can compete with valine for misrecognition by isoleucyl-tRNA synthetase (IleRS). Although this phenomenon is well characterized in microbial fermentation systems, norvaline has the highest destructive effect on β-sheet secondary structure, and the higher toxicity of norvaline over valine is predominantly due to misincorporation within β-sheet secondary elements. Whether orally supplemented norvaline reaches intracellular concentrations sufficient to cause measurable misincorporation in human proteins has not been established.

8.4 Long-Term Safety Data

No long-term human safety studies of L-norvaline supplementation have been published. There are no established maximum tolerated doses, no data on chronic (greater than a few weeks) dietary intake, and no regulatory agency assessments (such as EFSA, EMA, or NIH ODS) specifically evaluating L-norvaline's safety profile as a supplement ingredient. The NIH Dietary Supplement Label Database (DSLD) acknowledges norvaline's presence in commercially marketed products but does not provide a systematic safety review.

8.5 Potential Drug Interactions

By increasing nitric oxide bioavailability through arginase inhibition, L-norvaline could theoretically potentiate the effects of:

Nitrate-based medications (e.g., nitroglycerin, isosorbide dinitrate)
Phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil)
Antihypertensive medications

These potential interactions follow logically from the established mechanism of arginase inhibition and enhanced NO production. However, no specific drug interaction studies with L-norvaline have been published in human subjects. The inhibition of arginase has demonstrated to induce higher L-arginine availability and improved eNOS coupling, leading to increased NO and decreased superoxide production, a vascular effect that would be expected to augment the hypotensive effects of NO-potentiating drugs.

8.6 Special Populations

No studies on norvaline use in pregnant women, nursing mothers, children, or individuals with renal or hepatic impairment have been published. The urea cycle involvement of the arginine–arginase pathway is relevant to individuals with urea cycle disorders; arginase redirects the metabolism of L-arginine to L-ornithine and the formation of polyamines and L-proline, a pathway of critical importance in these conditions. Caution is warranted in any population in which urea cycle integrity is compromised, though this has not been investigated specifically with norvaline supplementation.

References

Health Conditions

Health conditions that Norvaline may help support.

No conditions available.

Body Systems

Body systems that Norvaline may help support.

No body systems available.